Search
Back 

NRG-LU002

NRG-LU002: Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Principal Investigator

Puneeth Iyengar, MD, PhD

Primary Objective

  • Phase II:  To evaluate the impact of adding SBRT to maintenance systemic therapy versus maintenance systemic therapy alone on progression-free survival for patients with metastatic NSCLC with no evidence of progression and limited metastatic sites after first-line systemic therapy
  • Phase III:  To evaluate the impact of adding SBRT to maintenance systemic therapy versus maintenance systemic therapy alone on overall survival for patients with metastatic NSCLC with no evidence of progression and limited metastatic sites after first-line systemic therapy

Patient Population

Metastatic non-small cell lung cancer (NSCLC) patients who have 3 or fewer metastatic sites (excluding primary) and exhibit at least stable disease after four cycles of first line/induction systemic therapy.

Target Accrual

300 patients

Status

Activation: April 5, 2017

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website

.
Copyright 2017 by NRG Oncology